Human Genome Epidemiology Literature Finder
|
Records 1 - 30 (of 33 Records) |
| Query Trace: Polycythemia Vera and ASXL1[original query] |
|---|
| Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon a-2a. Blood 2013 Aug 122 (6): 893-901. Quintás-Cardama Alfonso, Abdel-Wahab Omar, Manshouri Taghi, Kilpivaara Outi, Cortes Jorge, Roupie Anne-Laure, Zhang Su-Jiang, Harris David, Estrov Zeev, Kantarjian Hagop, Levine Ross L, Verstovsek Srd |
| Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group. American journal of hematology 2016 Apr . Rotunno Giada, Pacilli Annalisa, Artusi Valentina, Rumi Elisa, Maffioli Margherita, Delaini Federica, Brogi Giada, Fanelli Tiziana, Pancrazzi Alessandro, Pietra Daniela, Bernardis Isabella, Belotti Clara, Pieri Lisa, Sant'Antonio Emanuela, Salmoiraghi Silvia, Cilloni Daniela, Rambaldi Alessandro, Passamonti Francesco, Barbui Tiziano, Manfredini Rossella, Cazzola Mario, Tagliafico Enrico, Vannucchi Alessandro M, Guglielmelli Pao |
| Genetic Risk Assessment in Myeloproliferative Neoplasms. Mayo Clinic proceedings 2017 8 92 (8): 1283-1290. Tefferi Ayalew, Vannucchi Alessandro Mar |
| Comparison of the Mutational Profiles of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocytosis. American journal of clinical pathology 2017 May 147 (5): 444-452. Song Jinming, Hussaini Mohammad, Zhang Hailing, Shao Haipeng, Qin Dahui, Zhang Xiaohui, Ma Zhenjun, Hussnain Naqvi Syeda Mahrukh, Zhang Ling, Moscinski Lynn |
| TET2, ASXL1, IDH1, and IDH2 Single Nucleotide Polymorphisms in Turkish Patients with Chronic Myeloproliferative Neoplasms. Turkish journal of haematology : official journal of Turkish Society of Haematology 2017 Feb . Soyer Nur, Tezcanl? Kaymaz Burçin, Cömert Özkan Melda, Aktan Ça?da?, Küçükaslan Ali ?ahin, ?ahin Fahri, Kosova Buket, Saydam Gür |
| Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients. Blood cancer journal 2017 12 7 (12): 662. Cerquozzi S, Barraco D, Lasho T, Finke C, Hanson C A, Ketterling R P, Pardanani A, Gangat N, Tefferi |
| Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up. Annals of hematology 2017 11 97 (3): 443-451. Senín Alicia, Fernández-Rodríguez Concepción, Bellosillo Beatriz, Camacho Laura, Longarón Raquel, Angona Anna, Besses Carles, Álvarez-Larrán Alber |
| Targeted molecular characterization shows differences between primary and secondary myelofibrosis. Genes, chromosomes & cancer 2019 7 59 (1): 30-39. Courtier Frédéric, Garnier Séverine, Carbuccia Nadine, Guille Arnaud, Adélaide José, Chaffanet Max, Hirsch Pierre, Paz Damien Luque, Slama Bohrane, Vey Norbert, Ugo Valérie, Delhommeau François, Rey Jérome, Birnbaum Daniel, Murati An |
| Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation. Blood 2019 2 133 (20): 2233-2242. Gagelmann Nico, Ditschkowski Markus, Bogdanov Rashit, Bredin Swann, Robin Marie, Cassinat Bruno, Shahswar Rabia, Thol Felicitas, Heuser Michael, Socié Gerard, Beelen Dietrich, Triviai Ioanna, Badbaran Anita, Kröger Nicola |
| The Temporal Sequence and the Differences in Somatic Mutation Acquisition Determines Clinical Behaviors of JAK2-Positive Myeloproliferative Neoplasms. Anticancer research 2019 Nov 39 (11): 6273-6282. Byun Ja Min, Song Seulki, Koh Youngil, Yoon Sung-Soo, Kim Daeyo |
| Mutational profiling in myelofibrosis: implications for management. International journal of hematology 2019 10 111 (2): 192-199. Bose Prithviraj, Verstovsek Srd |
| [Analysis of gene mutations and clinic features in 108 patients with myeloproliferative neoplasm]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2020 8 41 (7): 576-582. Tan Y X, Xu N, Huang J X, Wu W E, Liu L, Zhou L L, Liu X L, Yin C X, Xu D, Zhou |
| A case of a primary myelofibrosis with progression and related literature review of progression phase genetics. International journal of laboratory hematology 2021 7 43 Suppl 1 78-81. Chen Dong, Fuda Franklin, Weinberg Ol |
| Impact of Integrated Genetic Information on Diagnosis and Prognostication for Myeloproliferative Neoplasms in the Next-Generation Sequencing Era. Journal of clinical medicine 2021 Mar 10 (5): . Lee Jong-Mi, Lee Howon, Eom Ki-Seong, Lee Sung-Eun, Kim Myungshin, Kim Yongg |
| Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases. American journal of hematology 2021 (7): 781-789. Gangat Naseema, Guglielmelli Paola, Szuber Natasha, Begna Kebede H, Patnaik Mrinal M, Litzow Mark R, Al-Kali Aref, Foran James M, Palmer Jeanne M, Alkhateeb Hassan, Elliott Michelle A, Hanson Curtis A, Pardanani Animesh, Mannelli Francesco, Vannucchi Alessandro M, Tefferi Ayal |
| Thiol/Disulfide Balance in Older Patients with BCR-ABL Negative Myeloproliferative Neoplasms. Clinical laboratory 2021 12 67 (12): . Koyuncu Mahmut B, Cavusoglu Cagatay, Basir Hakan, Ilgan Mustafa, Ucar Mehmet A, Akdeniz Aydan, Tombak Anil, Tiftik Eyup N, Temel Gulhan O, Neselioglu Salim, Erel Ozc |
| Combination of myeloproliferative neoplasm driver gene activation with mutations of splice factor or epigenetic modifier genes increases risk of rapid blastic progression. European journal of haematology 2021 1 106 (4): 520-528. Bartels Stephan, Vogtmann Julia, Schipper Elisa, Büsche Guntram, Schlue Jerome, Lehmann Ulrich, Kreipe Ha |
| [Analysis of the effect of gene mutations on the efficacy of ruxolitinib in patients with myelofibrosis based on second-generation sequencing technology]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2022 6 43 (4): 323-329. Tan Y X, Luo J, Huang J X, Luo D M, Liang H Y, Zhou X, Liu X L, Xu |
| Lab tests for MPN. International review of cell and molecular biology 2022 2 366 187-220. Moncada Alice, Pancrazzi Alessand |
| Non-driver gene mutation analysis in a large cohort of polycythemia vera and essential thrombocythemia. European journal of haematology 2022 Oct . Morishita Soji, Hashimoto Yoshinori, Furuya Chiho, Edahiro Yoko, Ochiai Tomonori, Shirane Shuichi, Inano Tadaaki, Yasuda Hajime, Ando Miki, Araki Marito, Komatsu Nor |
| JAK2V617F variant allele frequency, non-driver mutations, single-nucleotide variants and polycythemia vera outcome. Journal of cancer research and clinical oncology 2022 Oct . Kandu?a Zuzanna, Janowski Micha?, Wi?ckowska Barbara, Paczkowska Edyta, Lewandowski Krzyszt |
| Myeloid/Lymphoid Neoplasm with FGFR1 Rearrangement Presenting with Polycythemia Vera and T-cell Acute Lymphoblastic Leukemia. Cancer genetics 2023 7 276-277 43-47. Lisa M Marinelli, Joshua T Romain, William Ehman, Veronica Ortega, Gopalrao Velagaleti, Thomas F Gibbons, Ashley Nazario-Toole, Allen R Holm |
| Whole Exome Sequencing Reveals Novel Variants in Unexplained Erythrocytosis. Omics : a journal of integrative biology 2023 7 . Harshit Khurana, Babylakshmi Muthusamy, Uday Yanamandra, Kishore Garapati, Harikrishnan Premdeep, Shankar Subramanian, Akhilesh Pand |
| [Clinical characteristics and prognostic factors of patients with Philadelphia-negative myeloproliferative neoplasm accelerated/blast phase]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2023 6 44 (4): 276-283. X Yan, T J Qin, B Li, S Q Qu, L J Pan, F H Li, N N Liu, Z J Xiao, Z F |
| Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023 5 JCO2201935. Claire N Harrison, Jyoti Nangalia, Rebecca Boucher, Aimee Jackson, Christina Yap, Jennifer O'Sullivan, Sonia Fox, Isaak Ailts, Amylou C Dueck, Holly L Geyer, Ruben A Mesa, William G Dunn, Eugene Nadezhdin, Natalia Curto-Garcia, Anna Green, Bridget Wilkins, Jason Coppell, John Laurie, Mamta Garg, Joanne Ewing, Steven Knapper, Josephine Crowe, Frederick Chen, Ioannis Koutsavlis, Anna Godfrey, Siamak Arami, Mark Drummond, Jennifer Byrne, Fiona Clark, Carolyn Mead-Harvey, Elizabeth Joanna Baxter, Mary Frances McMullin, Adam J Me |
| [Analysis of risk factors for venous thromboembolism in patients with polycythemia vera and establishment of a prediction model]. Zhonghua yi xue za zhi 2024 7 104 (25): 2336-2341. J Y Ma, Y H Zhang, G S Teng, C X Du, H Q Zhang, Y Wang, Y Q Li, Y F Duan, Y Zhou, Z H Shao, J B |
| [Relationship between DTA Mutations and Thromboembolism in Patients with Myeloproliferative Neoplasms]. Zhongguo shi yan xue ye xue za zhi 2024 6 32 (3): 819-824. Min Wang, Hong-Yu Zhao, Da-Qi Li, Ping Ch |
| DNMT3A/TET2/ASXL1 mutations are an age-independent thrombotic risk factor in polycythemia vera patients: an observational study. Thrombosis and haemostasis 2024 1 . Adrián Segura-Díaz, Ruth Stuckey, Yanira Florido, Marta Sobas, Alberto Alvarez-Larran, Francisca Ferrer, Manuel M Pérez-Encinas, Gonzalo Carreño-Tarragona, María Laura Fox, Barbara Tazón Vega, Barbara Cuevas, Juan Francisco López Rodríguez, Nuria Farías-Sánchez, Jesús M González-Martín, María Teresa Gómez-Casares, Cristina Bilbao-Siey |
| Genomic classification and outcomes of young patients with polycythemia vera and essential thrombocythemia according to the presence of splanchnic vein thrombosis and its chronology. Annals of hematology 2024 1 . Marta Garrote, Mónica López-Guerra, Juan Carlos García-Pagán, Eduardo Arellano-Rodrigo, Francisca Ferrer-Marín, Juan Carlos Hernández-Boluda, Beatriz Bellosillo, Meritxell Nomdedeu, Virginia Hernández-Gea, Ana Triguero, Francesca Guijarro, José Álamo, Anna Baiges, Fanny Turon, Dolors Colomer, Francisco Cervantes, Alberto Alvarez-Larr |
| Idiopathic erythrocytosis: a germline disease? Clinical and experimental medicine 2024 1 24 (1): 11. E M Elli, M Mauri, D D'Aliberti, I Crespiatico, D Fontana, S Redaelli, S Pelucchi, S Spinelli, B Manghisi, F Cavalca, A Aroldi, A Ripamonti, S Ferrari, S Palamini, F Mottadelli, L Massimino, D Ramazzotti, G Cazzaniga, A Piperno, C Gambacorti-Passerini, R Piaz |
- Page last reviewed:Feb 1, 2024
- Content source: